SelectImmune Pharma AB publishes video from digital investor meeting

SelectImmune Pharma AB publishes video from digital investor’s meeting

SelectImmune Pharma AB has published a video from the digital investor’s meeting held in conjunction with the company's Annual General Meeting in November 2022. The video is now available on the company's website. In this video, chairman Catharina Svanborg and CEO Gabriela Godaly present provided an overview of the company's progress and discuss future goals for the development of infectious disease therapies. Positive results were presented for the treatment of Bladder Pain Syndrome with the drug candidate IL-1RA as well as an overview of the company's strategy for the development of new drugs against infectious diseases.

The company welcomes interested investors and the general public to access the information.

Link to video at homepage: http://www.selectimmune.com/invest

Link to video at youtube: https://youtu.be/lK3SMeaVqdY

SelectImmune Pharma AB 559104-6874

For more information, please contact:

Gabriela Godaly

CEO (acting), SelectImmune Pharma AB

Tel: +46 733 38 13 44

E-mail: gabriela.godaly@selectimmune.com

Catharina Svanborg

Chairman SelectImmune Pharma AB

Tel: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company develops new immunotherapies, which act as immune modulators and offer complements to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are extremely common, affecting at least 50% of all women. There is an immediate need for treatment alternatives and the potential markets are very large.